Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Manufacturing Services AgreementManufacturing Services Agreement • March 16th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • England
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. KEY INTERMEDIATE SUPPLY AGREEMENTKey Intermediate Supply Agreement • March 16th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS KEY INTERMEDIATE SUPPLY AGREEMENT (this “Agreement”) is made as of this 28th day of August 2017 (“Effective Date”), by and among NABRIVA THERAPEUTICS IRELAND DAC (“NABRIVA”), and SEL BIOCHEM XINJIANG CO., LTD (“SEL”) and FOUNTAIN INTERNATIONAL DEVELOPMENT HOLDING LIMITED (“FOUNTAIN”). NABRIVA, SEL, and FOUNTAIN are hereinafter collectively referred to as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. MASTER AGREEMENT FOR THE MANUFACTURE, PACKAGING AND SUPPLY OF PRODUCTSMaster Agreement for the Manufacture, Packaging and Supply of Products • March 16th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • England
THIS AGREEMENT is made on the 7th day of August, 2017 between ALMAC PHARMA SERVICES LIMITED, (No. NI45055) whose registered office is at Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, Northern Ireland (“ALMAC”); and NABRIVA THERAPEUTICS IRELAND DAC, having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (the “Client”)
